[
    {
        "title": "Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating ... - Merck",
        "description": "Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating ...  Merck",
        "published date": "Fri, 22 Sep 2023 07:00:00 GMT",
        "url": "https://consent.google.com/m?continue=https://news.google.com/rss/articles/CBMi0gFodHRwczovL3d3dy5tZXJjay5jb20vbmV3cy9tZXJjay1hbmQtZWlzYWktcHJvdmlkZS11cGRhdGUtb24tdHdvLXBoYXNlLTMtdHJpYWxzLWV2YWx1YXRpbmcta2V5dHJ1ZGEtcGVtYnJvbGl6dW1hYi1wbHVzLWxlbnZpbWEtbGVudmF0aW5pYi1pbi1wYXRpZW50cy13aXRoLWNlcnRhaW4tdHlwZXMtb2YtbWV0YXN0YXRpYy1ub24tc21hbGwtY2VsbC1sdW5nLWNhbmNlci_SAQA?oc%3D5&gl=IT&m=0&pc=n&cm=2&hl=en-US&src=1"
    },
    {
        "title": "Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual ... - Merck",
        "description": "Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual ...  Merck",
        "published date": "Fri, 22 Sep 2023 10:06:32 GMT",
        "url": "https://consent.google.com/m?continue=https://news.google.com/rss/articles/CBMi3wFodHRwczovL3d3dy5tZXJjay5jb20vbmV3cy9tZXJjay1hbm5vdW5jZXMtcGhhc2UtMy1rZXlub3RlLWEzOS1ldi0zMDItdHJpYWwtbWV0LWR1YWwtcHJpbWFyeS1lbmRwb2ludHMtb2Ytb3ZlcmFsbC1zdXJ2aXZhbC1vcy1hbmQtcHJvZ3Jlc3Npb24tZnJlZS1zdXJ2aXZhbC1wZnMtaW4tY2VydGFpbi1wYXRpZW50cy13aXRoLXByZXZpb3VzbHktdW50cmVhdGVkLWxvY2FsbHktYWR2YW5jZWQv0gEA?oc%3D5&gl=IT&m=0&pc=n&cm=2&hl=en-US&src=1"
    }
]